Rhythm Pharmaceuticals (RYTM)
(Delayed Data from NSDQ)
$51.06 USD
-1.74 (-3.30%)
Updated Sep 23, 2024 04:00 PM ET
After-Market: $51.08 +0.02 (0.04%) 6:18 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Income Statements
Fiscal Year end for Rhythm Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 77 | 24 | 3 | 0 | 0 |
Cost Of Goods | 9 | 2 | 1 | 0 | 0 |
Gross Profit | 68 | 22 | 3 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 252 | 201 | 173 | 137 | 146 |
Income After Depreciation & Amortization | -184 | -179 | -170 | -137 | -146 |
Non-Operating Income | 14 | 3 | 100 | 3 | 5 |
Interest Expense | 14 | 5 | 0 | 0 | 0 |
Pretax Income | -184 | -181 | -70 | -134 | -141 |
Income Taxes | 1 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -185 | -181 | -70 | -134 | -141 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -185 | -181 | -70 | -134 | -141 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -169 | -172 | -169 | -136 | -145 |
Depreciation & Amortization (Cash Flow) | 15 | 7 | 1 | 1 | 1 |
Income After Depreciation & Amortization | -184 | -179 | -170 | -137 | -146 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 57.67 | 52.12 | 49.60 | 44.13 | 36.42 |
Diluted EPS Before Non-Recurring Items | -3.20 | -3.47 | -1.40 | -3.04 | -3.86 |
Diluted Net EPS (GAAP) | -3.20 | -3.47 | -1.40 | -3.04 | -3.86 |
Fiscal Year end for Rhythm Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 29.08 | 25.97 | 24.23 | 22.50 | 19.22 |
Cost Of Goods | 2.95 | 2.81 | 3.23 | 2.41 | 2.24 |
Gross Profit | 26.13 | 23.16 | 21.00 | 20.09 | 16.99 |
SG&A, R&D, and Dept/Amort Expenses | 66.61 | 163.05 | 62.27 | 64.05 | 63.59 |
Income After SG&A, R&D, and Dept/Amort Expenses | -40.48 | -139.89 | -41.27 | -43.96 | -46.60 |
Non-Operating Income | 13.30 | 3.57 | 4.21 | 3.31 | 3.20 |
Interest Expense | 4.60 | 4.76 | 4.38 | 3.15 | 3.30 |
Pretax Income | -31.78 | -141.07 | -41.44 | -43.80 | -46.70 |
Income Taxes | 0.48 | 0.30 | 0.20 | 0.37 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -32.26 | -141.37 | -41.63 | -44.16 | -46.70 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -32.26 | -141.37 | -41.63 | -44.16 | -46.70 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 61.01 | 60.14 | 59.21 | 57.88 | 56.87 |
Diluted EPS Before Non-Recurring Items | -0.55 | -2.35 | -0.70 | -0.76 | -0.82 |
Diluted Net EPS (GAAP) | -0.55 | -2.35 | -0.70 | -0.76 | -0.82 |